Dx & Vx Co., Ltd. 180400
KRX · South Korea · Health Technology
KRW 2,365.00+25.00 (+1.07%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Dx&Vx (DXVX, KRX: 180400), a biopharmaceutical company, announced that it signed two material transfer agreements (MTAs) in Latin America within a two-month span in July and August, both related to its room-temperature, long-term nucleic acid stabilization platform, KRNA. Following its first Latin American agreement with an Argentine biopharmaceutical company in July, the company signed a second agreement in August with one of the region's leading public health institutions, securing validation
Dx&Vx has successfully expanded its global partnering initiatives at the BIO International Convention 2026 (BIO USA), raising the visibility of its overseas out-licensing opportunities.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.